Vast Therapeutics Announces Series A Funding.
Dec 5, 2018
(Durham, NC: December 5, 2018) Vast Therapeutics, Inc. (Vast) announced today that it has completed its Series A financing with a single investor, Shionogi & Co., Ltd. of Japan. The investment provides Vast with funding to advance their novel nitric oxide powder platform through pre-clinical testing and first-in-human clinical safety and efficacy trials during the next …
Vast Therapeutics (formerly Novoclem) Announces Results.
May 22, 2018
DURHAM, N.C., May 22, 2018 /PRNewswire/ — Vast Therapeutics, Inc., formerly Novoclem Therapeutics, Inc. (the Company), a preclinical stage pharmaceutical company focused on delivering the power of nitric oxide (NO) in a synthetically derived powder-based form, announced today that the Company’s first controlled NO-release powder based ..
Anne Whitaker keynote speaker for Novoclem Therapeutics, Inc.
Feb 27-28, 2018
The Council for Entrepreneurial Development hosted the 27th annual CED Life Science Conference on February 27-28, 2018 in Raleigh, NC. As the premier life science event in the Southeast, the conference attracted nearly 1,000 attendees including trailblazing entrepreneurs, investors, corporate leaders, and industry visionaries from across the nation.
Sign up for Email Alerts
Please fill out the form below to receive company press releases via email when they occur.